LTR Pharma (ASX: LTP) has announced positive interim Phase II clinical data for its SPONTAN intranasal PDE5 therapy alongside an investor presentation detailing its US strategy and funding.
Interim Phase II pharmacokinetic (PK) data for SPONTAN intranasal vardenafil showed a median time to maximum plasma concentration (Tmax) of 10 minutes for the 5 mg dose.
This is significantly faster than oral vardenafil, which had a median Tmax of 60 minutes.
The data, gathered from 27 subjects including a geriatric cohort of 14 subjects, indicated no serious adverse events or Grade 3/4 treatment-emergent adverse events.
Importantly, repeat dosing for 5 days showed no evidence of drug accumulation, with an accumulation ratio of 1.0±0.9.
These interim PK results reportedly meet key FDA Pre-IND requirements and are expected to inform LTR Pharma's planned FDA 505(b)(2) regulatory pathway, with final statistical results anticipated in Q3 CY2026.
Dual US Strategy Detailed
LTR Pharma is pursuing a dual US strategy for its erectile dysfunction treatments, advancing SPONTAN via the FDA 505(b)(2) pathway, while targeting earlier US market entry for ROXUS through 503A personalised medicine discussions.
The company has completed extractables studies, with leachables and human factors studies currently underway to support the complex FDA combination product requirements for its intranasal drug-device program.
Strategic partnerships with Aptar Pharma for co-development and manufacturing, and Mayne Pharma for commercial manufacturing, underpin this progress.
In Australia, the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) program has provided early validation, with more than 1,000 prescriptions recorded.
This real-world usage and expanding prescriber adoption offer valuable insights and support ahead of potential U.S. commercialisation.
Funding Position and Milestones
LTR Pharma reported a strong financial position, with $24.1 million in cash and zero debt.
The company states this is sufficient to fund operations and reach near-term clinical and regulatory milestones.
The current cash balance is intended to support crucial activities, including the completion of Phase II data readout, human factors, and toxicology studies.
Key upcoming milestones for 2026 include the completion of human factors and leachables studies in H1 2026, with the full Phase II dataset and final results expected in Q3 CY2026.
This will be followed by animal toxicology completion and Phase III planning.
Prior Progress and Risks
Previous reports from March 2026 indicated the completion of recruitment for the SPONTAN Phase II study, with initial data expected in Q2 2026.
The company’s 1H FY26 report showed widening losses, but its cash position remained robust, providing a runway for its programs.
While the interim data is positive, regulatory execution risk remains for the FDA combination product requirements and acceptance of the development plan.
Additionally, early US market presence via 503A discussions is progressing but not yet confirmed as executed.
Final Phase II results will provide further clarity on the drug's profile and support regulatory submissions.
With sufficient funding to reach upcoming milestones, the company is positioning itself for potential US market entry, though regulatory hurdles and execution remain key considerations.
